Cargando…

Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis

Paraneoplastic rheumatic syndromes comprise a heterogeneous group of disorders characterized by typical rheumatic manifestations but without direct invasion by the tumor or metastases. The clinical features and malignancy-associated risk factors of 21 patients with paraneoplastic rheumatic syndromes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Jian, Ouyang, Han, Yang, Ru, Bo, Lin, Zhang, Yi, Tang, Mei, Liu, Zhichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789019/
https://www.ncbi.nlm.nih.gov/pubmed/29379092
http://dx.doi.org/10.1038/s41598-018-20167-w
_version_ 1783296186730414080
author Wen, Jian
Ouyang, Han
Yang, Ru
Bo, Lin
Zhang, Yi
Tang, Mei
Liu, Zhichun
author_facet Wen, Jian
Ouyang, Han
Yang, Ru
Bo, Lin
Zhang, Yi
Tang, Mei
Liu, Zhichun
author_sort Wen, Jian
collection PubMed
description Paraneoplastic rheumatic syndromes comprise a heterogeneous group of disorders characterized by typical rheumatic manifestations but without direct invasion by the tumor or metastases. The clinical features and malignancy-associated risk factors of 21 patients with paraneoplastic rheumatic syndromes, including 11 men and 10 women with a mean age of 56.3 ± 13.1 years, were characterized by a retrospective review. All patients were diagnosed with malignancy within 2 years of rheumatism diagnosis. Patients suffering from solid malignancies accounted for the majority (62%); hematological malignancies were observed in the remainder. Arthritis (48%), lymph node enlargement (38%), skin rash (38%), weight loss (29%), fever/chills (24%), fatigue (24%), muscle soreness (24%) and smoking history (29%) were common findings. Except for 8 patients (38%) who tested positive for anti-nuclear antibody (ANA) and 9 positive for rheumatoid factor (RF), all patients tested negative for anti-extractable nuclear antigen (ENA) antibodies. Rheumatic disorders with a typical clinical presentation in older patients and nonspecific systemic features should alert clinicians to search for an occult malignancy. Patients with rheumatic disease must be closely followed to screen for malignancies, particularly within 2 years of rheumatism diagnosis.
format Online
Article
Text
id pubmed-5789019
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-57890192018-02-08 Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis Wen, Jian Ouyang, Han Yang, Ru Bo, Lin Zhang, Yi Tang, Mei Liu, Zhichun Sci Rep Article Paraneoplastic rheumatic syndromes comprise a heterogeneous group of disorders characterized by typical rheumatic manifestations but without direct invasion by the tumor or metastases. The clinical features and malignancy-associated risk factors of 21 patients with paraneoplastic rheumatic syndromes, including 11 men and 10 women with a mean age of 56.3 ± 13.1 years, were characterized by a retrospective review. All patients were diagnosed with malignancy within 2 years of rheumatism diagnosis. Patients suffering from solid malignancies accounted for the majority (62%); hematological malignancies were observed in the remainder. Arthritis (48%), lymph node enlargement (38%), skin rash (38%), weight loss (29%), fever/chills (24%), fatigue (24%), muscle soreness (24%) and smoking history (29%) were common findings. Except for 8 patients (38%) who tested positive for anti-nuclear antibody (ANA) and 9 positive for rheumatoid factor (RF), all patients tested negative for anti-extractable nuclear antigen (ENA) antibodies. Rheumatic disorders with a typical clinical presentation in older patients and nonspecific systemic features should alert clinicians to search for an occult malignancy. Patients with rheumatic disease must be closely followed to screen for malignancies, particularly within 2 years of rheumatism diagnosis. Nature Publishing Group UK 2018-01-29 /pmc/articles/PMC5789019/ /pubmed/29379092 http://dx.doi.org/10.1038/s41598-018-20167-w Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Wen, Jian
Ouyang, Han
Yang, Ru
Bo, Lin
Zhang, Yi
Tang, Mei
Liu, Zhichun
Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title_full Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title_fullStr Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title_full_unstemmed Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title_short Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis
title_sort malignancy dominated with rheumatic manifestations: a retrospective single-center analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789019/
https://www.ncbi.nlm.nih.gov/pubmed/29379092
http://dx.doi.org/10.1038/s41598-018-20167-w
work_keys_str_mv AT wenjian malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT ouyanghan malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT yangru malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT bolin malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT zhangyi malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT tangmei malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis
AT liuzhichun malignancydominatedwithrheumaticmanifestationsaretrospectivesinglecenteranalysis